Bacillus coagulans GBI-30, 6086

Safety profile

Across 3 clinical studies, no specific adverse events were quantitatively reported for Bacillus coagulans GBI-30, 6086. The probiotic was described as well tolerated in all studies, with no treatment-related adverse events or serious adverse events noted. One study also reported improvement in chronic gastrointestinal symptoms, though this reflects efficacy rather than a safety finding.

Caveats: Limited evidence base; absence of reports does not establish safety. Studies were primarily short-term (up to 8 weeks) and may have been powered for efficacy rather than safety, meaning rare adverse events may not have been detected. Findings are specific to the GBI-30, 6086 strain and may not generalize to other formulations.